The placebo response in Parkinson's disease

Clinical Neuropharmacology

Volumn 22, Issue 4, 1999, Pages 207-212

  Shetty, Neetha ^a   Friedman, Joseph H ^a,b,d   Kieburtz, Karl ^c   Marshall, Frederick J ^c   Oakes, David ^c  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Parkinson's disease; Placebo; Placebo controlled trial

Indexed keywords

PLACEBO; SELEGILINE; TOCOPHEROL;

ARTICLE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

FEMALE; HUMANS; MALE; PARKINSON DISEASE; PLACEBO EFFECT; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 0033405084     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Grunbaum A. The placebo concept in medicine and psychiatry. Psychol Med 1986; 16:19-38.
2. Shapiro A. A historic and heuristic definition of the placebo. Psychiatry 1960;27:52-8.
3. Sullivan MD. Placebo controls in epistemic control in orthodox medicine. J Med Philos 1993;18:213-31.
4. Moertel CG, Taylor RF, Roth A, et al. Who responds to sugar pills? Mayo Clin Proc 1976;51:96-100.
5. Packer M. The placebo effect in heart failure. Am Heart J 1990;120: 1579-82.
6. Archer TP, Leier CV. Placebo treatment in congestive heart failure. Cardiology 1992;81:125-33.
7. Backman H, Kalliola H, Ostling G. Placebo effect in peptic ulcer and gastroduodenal disorders. Gastroenterolgia 1960;94:11-20.
8. Bensen H, McCallie DP. Angina pectoris and placebo effect. N Engl J Med 1979;300:1424-9.
9. Amsterdam EA, Wolfson S, Goolin R. New aspects of placebo response in angina pectoris. Am J Cardiol 1969;2:305-6.
10. Remington G, Fornazzari L, Sethna R. Placebo response in tardive akathisia. Can J Psychiatr 1993;38:248-50.
11. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15(suppl 1):36-44.
12. Fairchild CJ, Rush AJ, Vasavada N, et al. Which depressions respond to placebo? Psychiatr Res 1986;18:217-26.
13. Laporte JR, Figueras A. Placebo effects in psychiatry. Lancet 1994; 344:1206-9.
14. Berman I, Sapers BL, Chang HH, et al. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol 1995;15:206-10.
15. Rosenberg NK, Mellergard M, Rosenberg R, et al. Characteristics of panic disorder patients responding to placebo. Acta Psychiatr Scand Suppl 1991;365:33-8.
16. Evans, FJ. The power of the sugar pill. Psychology Today, April 1974; pp. 55-9.
17. Kelkar P, Ross MA. Natural history of disease and placebo effect. Perspect Biol Med 1994;37:244-6.
18. Bystritsky A, Waikar MA. Inert placebos vs. active medication: patient blindability in clinical pharmacological trials. J Nerv Ment Dis 1994;182:485-7.
19. Tetrud JW, Langston JW. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. J Neural Transm Suppl 1987;25:69-79.
20. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-14.
21. Rosenzweig P, Brohier S, Zipfel A. The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase I studies. Br J Clin Pharmacol 1995;39: 657-64.
22. Gowdey CW. A guide to the pharmacology of placebos. Can Med Assoc J 1983;128:921-5.
23. Shapiro A. Placebo effects in psychotherapy and psychoanalysis. J Clin Pharmacol 1970;10:73-8.
24. Wilcox CS, Cohn JB, Linden R, et al. Predictors of placebo response: A retrospective analysis. Psychopharmacol Bull 1992;28: 157-62.
25. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatr Res 1992;41:203-14.
26. Buckalew LW, Ross S, Starr BJ. Nonspecific factors in drug effects: placebo personality. Psychol Rep 1981;48:3-8.
27. Fisher S. The placebo reactor: thesis, antithesis, synthesis and hypothesis. Dis Nerv Syst 1967;28:510-5.
28. Shoulson I and the Parkinson Study Group. DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;49:1052-60.
29. Schawb RS, England AC Jr. Projection technique for evaluating surgery in Parkinson's disease. In: Gilligham FJ, Donaldson IM. eds. Third Symposium on Parkinson's Disease. Edinburgh: E & S Livingstone; 1969:152-7.
30. Hoehn MM, Yahr MD. Parkinsonism: onset, progression & mortality. Neurology 1967;17:427-42.
31. Jensen MP, Karoly P. Motivation and expectancy factors in symptom perception: a laboratory study of the placebo effect. Psychosom Med 1991;53:144-52.
32. Shepard M. The placebo: From specificity to non-specificity and back. Psychol Med 1993;23:569-78.
33. Bogdanoff MD. The doctor-patient relationship. JAMA 1965; 192:45-48.